Yahoo Finance

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Investing

Recursion Pharmaceuticals maintains $12 target with Phase 2 success

On Tuesday, KeyBanc reaffirmed its Overweight rating and $12.00 price target for Recursion Pharmaceuticals (NASDAQ:RXRX), following the announcement of Phase 2 trial results for REC-994. The ...
manilatimes

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target ...

Recursion Pharmaceuticals, Inc. Class A

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Investing

KeyBanc maintains $12 target on Recursion Pharmaceuticals post-acquisition

On Wednesday, KeyBanc Capital Markets maintained its Overweight rating on Recursion Pharmaceuticals (NASDAQ:RXRX) with a steady price target of $12.00. The affirmation follows Recursion's recent ...
manilatimes

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds ...